News

As per the agreement, Concert will receive an upfront payment and upon achievement of certain predefined clinical, regulatory and commercial targets, it is eligible to receive additional milestone

Opexa is developing Tovaxin, a novel T-cell therapy for multiple sclerosis (MS). Opexa president and chief executive officer Neil Warma said they are pleased with the depth of

Under the agreement, arGEN-X will receive an upfront technology access fee, research funding and preclinical success payments, and in return for its option to develop and commercialize products,

The company has gained an exclusive, worldwide license to intellectual property surrounding the tumor-associated antigen mesothelin, which is highly expressed in pancreatic cancer, ovarian cancer and mesothelioma. The

The product, which contains 0.25mg drospirenone (drsp)/0.5mg estradiol (E2), will be available in the US by prescription shortly, the company said. The new formulation significantly reduces the occurrence

The company will be responsible for manufacturing and supply of an injectable anesthetic agent. JHP president and CEO Stuart Hinchen said the company successfully completed an FDA (CBER)

Levetiracetam oral solution is used to treat partial onset seizures in people 16 years of age and older with epilepsy. The company expects to launch the product by

FluMist Quadrivalent contains four strains (two type A strains and two type B lineages) to help provide broad protection against circulating influenza A and B. The quadrivalent vaccine

As per the agreement, Abbott will make an initial upfront payment of $150m for rights related to the global collaboration. Upon successful completion of the RA Phase II